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Development and Application of 
a Functional Human esophageal 
Mucosa explant platform to 
eosinophilic esophagitis
Richard C. Kurten1,2,3, Renee Rawson4, Tetsuo shoda5, Loan D. Duong4, Dolapo Adejumobi1,2,3,  
Rebecca Levy3,6, Robert O. Newbury7, Marc E. Rothenberg  5, Praveen Akuthota8,11, 
Benjamin L. Wright9, Ranjan Dohil4,10, Stacie M. Jones2,3 & seema s. Aceves2,4,11
There is an increasing prevalence of esophageal diseases but intact human tissue platforms to study 
esophageal function, disease mechanisms, and the interactions between cell types in situ are lacking. to 
address this, we utilized full thickness human donor esophagi to create and validate the ex vivo function 
of mucosa and smooth muscle (n = 25). Explanted tissue was tested for contractile responses to carbachol 
and histamine. We then treated ex vivo human esophageal mucosa with a cytokine cocktail to closely 
mimic the Th2 and inflammatory milieu of eosinophilic esophagitis (EoE) and assessed alterations in 
smooth muscle and extracellular matrix function and stiffening. We found that full thickness human 
esophagus as well as the individual layers of circular and longitudinal muscularis propria developed 
tension in response to carbachol ex vivo and that mucosa demonstrated squamous cell differentiation. 
Treatment of mucosa with Th2 and fibrotic cytokines recapitulated the majority of the clinical Eosinophilic 
Esophagitis Diagnostic Profile (EDP) on fluidic transcriptional microarray. Transforming growth factor-
beta-1 (TGFβ1) increased gene expression of fibronectin, smooth muscle actin, and phospholamban 
(p < 0.001). The EoE cocktail also increased stiffness and decreased mucosal compliance, akin to the 
functional alterations in eoe (p = 0.001). This work establishes a new, transcriptionally intact and 
physiologically functional human platform to model esophageal tissue responses in EoE.
Food transit through the esophagus involves a complex interplay of mucosa to provide lubrication and barrier 
function, muscle layers for propulsion, and enteric and central innervation for coordinated transport of food to 
the stomach. Proper function is essential to adequate nutritional intake. A rise in esophageal disorders including 
gastroesophageal reflux, EoE1, and esophageal carcinoma2 drives a need for human disease-relevant experimental 
platforms.
While murine models can recapitulate human disease, in the esophagus there are a number of structural 
cell differences between species3. The human esophagus transitions to smooth muscle more proximally than the 
murine esophagus. The epithelium is keratinized in mice but not in humans. The innervation of the human and 
murine esophagus is distinct so motility disturbances can be challenging to assess in mice3. These structural and 
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functional differences combined with evolving questions of general translatability of murine disease models to 
human polygenic diseases underscores a need for intact human platforms to experimentally manipulate human 
esophageal cells within their natural environment. Feline, opossum and guinea pig esophageal models have been 
utilized to study esophageal function4,5, and these species are closer to the human esophagus in terms of structural 
cells and innervation, yet they remain distinct species and the study of human esophageal disease would generally 
benefit from a widely applicable human esophageal platform.
One esophageal disease of rising prevalence is EoE. EoE is diagnosed when ≥15 eosinophils per high power 
field are present in the esophageal epithelium1,6. Progressive tissue remodeling with fibrosis in children and adults 
causes esophageal rigidity, lost tissue compliance, and resultant food impactions and strictures7–13. Dysmotility 
is an increasingly appreciated consequence of unbridled Th2 inflammation in EoE11,14–19. Current investigational 
platforms for EoE include small biopsies13,19, isolated structural cells13,19,20, spheroids21,22, and immortalized epi-
thelial cells23,24. While studies of spheroids are feasible and represent 3-dimensional tissues, they require disper-
sion and re-juxtapositioning of cells and therefore cannot entirely represent the function of an intact epithelium 
or its interactions with neighboring cells such as smooth muscle21,23,25.
To address the experimental need for a human esophageal platform, we systematically characterized the base-
line and induced functional and transcriptional alterations in intact human tissue cultured ex vivo. We utilized 
full thickness mucosal tissue and isolated longitudinal and circular smooth muscle bundles in functional tension 
response studies. Treatment of intact mucosa with a cytokine cocktail containing Th2 and pro-fibrotic cytokines 
increased mucosal stiffness and induced an EoE-like gene transcription profile. To our knowledge, this is the 
first utilization of intact human esophageal tissue explants to model a disease state both physiologically and 
transcriptionally.
Results
Isometric tension studies. Intact esophageal rings. Carbachol treatment of intact rings from the distal 
half of the human esophagus hung immediately after preparation increased isometric force (Fig. 1a, arrow). This 
response was retained after storage at 7 °C for 24 hours and persisted after removal of the mucosal layer (Fig. 1b). 
Responses were characterized by a peak within minutes that decayed to a stable plateau. These results indicate 
esophageal tissues retain contractile function ex vivo for at least 24 hours post acquisition.
Individual tissue layers. The inner circular smooth muscle (CSM) layer of the muscularis propria is oriented 
in the appropriate direction for tension development in esophageal rings. To confirm that CSM generated the 
Figure 1. Induced force responses in human esophageal smooth muscle. Contractile forces were generated in 
response to carbachol under isometric conditions in (a) freshly isolated intact tissue rings (n = 3 donors) and 
(b) muscularis proria rings after storage at 7 °C for 24 hours (4th donor). Arrows indicate carbachol addition. 
Carbachol induces concentration-dependent force responses in: (c) isolated circular smooth muscle rings, 
(d) longitudinal smooth muscle bundles (n = 4, cultured for 1 day), and (e) mucosal strips (n = 4, cultured for 
1 day). (f) Histamine (H) stimulates LSM bundle contraction independently of carbachol (C) and forces are 
attenuated by isoproterenol (I) (4 bundles, cultured for 3 days). (g) Induced tension responses (1 μM carbachol) 
in microdissected MM (p = 0.25, n = 8, cultured 3–5 days).
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majority of the observed tension in the full thickness esophagus, we dissected away the mucosa and found that 
contractile response to carbachol was retained (Fig. 1c).
Diffusion limited nutrient and metabolite exchange precluded long-term ex vivo culture of intact esophageal 
rings. Moreover, estimates of the tension contributions by longitudinal smooth muscle (LSM) and muscularis 
mucosa (MM) (where the muscle is longitudinally oriented) cannot be determined in rings due to tissue orien-
tation. We therefore isolated tissue strips (~15 × 1 × 1 mm, Fig. S2) from each esophageal layer (mucosa, LSM, 
and CSM), cultured them for 1–5 days as indicated, and transferred them to organ baths for measurement of 
isometric tension responses. Carbachol stimulated dose-dependent increases in isometric force in LSM stretched 
longitudinally (Fig. 1d). Mucosa also generated tension along the longitudinal axis upon treatment with carbachol 
(Fig. 1e), consistent with the orientation of the MM. Histamine induced LSM tension that was augmented by 
10 μM carbachol and reduced by the β-agonist isoproterenol (Fig. 1f). Carbachol also induced isometric tension 
in microdissected MM preparations (Fig. 1g). By contrast, in mucosa stretched along the circular axis, carbachol 
did not induce isometric tension (data not shown). These results indicate that the three smooth muscle layers of 
the human esophagus as well as the full thickness mucosa can be separated and maintained to retain their con-
tractile responses ex vivo for at least 3–4 days.
Analysis of tissue stiffness. Some esophageal disorders such as EoE increase esophageal rigidity. To under-
stand if we could induce functional alterations in the ex vivo platform that partially mimic a chronic esophageal 
disease, we assessed esophageal stiffness in the intact mucosa after culture for 3 days. We began by characterizing 
the baseline stiffness of individual tissue layers using sequential cycles of lengthening. In cycle 1 (Fig. 2a), the 
lengthening of mucosal tissue was only partly reversible since the tissue failed to return to its starting baseline 
length (red line). In cycle 2 (Fig. 2b), lengthening was reversible although the starting length was about twice that 
for cycle 1. When treated with 1 μM carbachol after cycle 2 (Fig. 2c), the mucosal tissue generated force and short-
ened to less than the starting length for cycle 1 at preload tension. In tension versus strain measurement cycle 3 
(Fig. 2d), the lengthening was completely reversible.
The data in Fig. 2a–d were reduced to time-integrated tension versus strain curves for mucosal lengthen-
ing (Fig. 2e) with tissue stiffness indicated by the slope of the curves. The curves were never linear, indicating 
that stiffness is length-dependent and that mucosal tissue is a hyperelastic material like rubber on lengthening. 
However, by contrast to rubber, the stretched mucosa failed to return to its original length on shortening in 
Figure 2. Tension versus strain measurements to determine stiffness. After culture for 3 days, tension 
measurements were collected from intact mucosa during sequential cycles (a,b) of stepwise lengthening 
followed by stepwise shortening of the same esophageal mucosa strip. Lengthening was reversed at a force 
threshold set to avoid tissue damage. Shortening was reversed as the force approached zero. The step tracings 
indicate the length (L, right y-axis) at which the tissue was held for 2 minute intervals as length was changed in 
0.72 mm increments. (a) In strain cycle 1, tissue tension (black line) but not length (red line) reached baseline 
on stepping down and (b) this remained the case in strain cycle 2. (c) 1 μM carbachol increases tension and 
shortening to less than the starting length. (d) In strain cycle 3 the tissue shortens to the starting length. 
(e) Integrated tension measurements plotted as a function of strain. (f) Plots generated from panel e data 
by subtracting cycle 2 from cycle 1 (basal) or cycle 3 (induced). (g) LSM bundle tension versus strain plots 
collected after culture for 10 days. (h) Contribution of smooth muscle to tissue tension in in basal and induced 
states for the LSM in panel g.
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cycle 1 (Fig. 2b), leading to a distinct rightward shift in the tension versus strain curve for lengthening in cycle 
2 (Fig. 2e). While tissue in the basal state (cycle 1, black squares) exhibits increasing stiffness gradually as it is 
stretched from L0 to 2.5x L0, the same tissue in cycle 2 (open circles) is infinitely compliant (stiffness = 0) from 
L0 to 2x L0, and rapidly stiffens from 2x to 2.5x L0. These observations led us to hypothesize that two additive 
elements contribute to the stiffness of the human esophageal mucosa. One element, lost by stretching the tissue, 
is contributed by smooth muscle. Another element, revealed in cycle 2 is likely a cross-linked biological polymer 
of the mucosal extracellular matrix, such as collagen-1. If basal stiffness is a combination of smooth muscle and 
extracellular matrix, then carbachol treatment to increase muscle force generation should restore the stiffness 
lost in the region of 1x to 2x L0 after stretch cycle 1. Indeed, treatment with carbachol resulted in a convincing 
leftward shift of the tension versus strain curve for cycle 3 (open squares, Fig. 2e). As further confirmation for 
the proposed role of smooth muscle in restoring of basal tissue stiffness after stretching, we subtracted the cycle 
2 (extracellular matrix) length versus tension curve from the cycle 1 (basal) curve or from the cycle 3 (induced) 
curve (Fig. 2f). The difference curves exhibited peaks of maximum tension development at ~2.5x L0. Such curves 
are characteristic of active force generation by muscle cells26,27 where maximal tension corresponds to maximal 
overlap of force generating myosin and actin filaments. LSM bundles exhibited similar properties after culture for 
10 days (Fig. 2g,h) with maximum basal and induced tension more similar than observed for mucosa.
The tension versus strain data was best fit by a power function: Tension = A (L/L0)k where A is the resting 
tension, L/L0 is the strain, and k > 1 indicates tissue stiffening on lengthening. Tissue stiffness is readily calculated 
from the derivative of the power function (=Ak(L/L0)k−1) where Ak gives the stiffness at L0. While both A and 
k contribute to measured stiffness, the calculated value for A is dependent on an accurate measurement of L0 
whereas the value calculated for k is independent of L0. Accurately measuring L0 is a challenge, so k is the most 
reliable parameter for statistical comparisons. We observed significant increases in k after stretching (Fig. 3a, 
clear bars) that could be restored to near basal values by treatment with contractile agonist in each esophageal 
layer (Fig. 3a, black bars). The magnitude of tension responses to carbachol were variable, with significantly less 
carbachol induced tension in circular smooth muscle than in longitudinal smooth muscle or in mucosa (Fig. 3b).
Taken together, A and k in the power function accurately model the composite mechanical stiffness properties 
of smooth muscle and extracellular matrix. In the absence of smooth muscle contractile system activation, tissue 
stretches with little resistance to strain (A is small, tissue is compliant) until it reaches a threshold between 1.5 
and 2.5 times resting length where it becomes very stiff as the limits to ECM strain are reached. In the presence 
of basal or induced smooth muscle tone, the tissue becomes stiffer at the resting length, and hence becomes less 
distensible. Together these results reveal that 1) combined properties of extracellular matrix and smooth mus-
cle determine the composite stiffness of the esophagus, 2) acetylcholine and histamine acutely regulate stiffness 
through the actin-myosin machinery, and 3) we can use this approach to characterize both extracellular matrix 
and smooth muscle contributions to human esophageal muscle tissue tension and stiffness.
Inducing a disease phenotype ex vivo. In addition to retention of smooth muscle function, the basal 
epithelial cell layer of mucosal explants was also preserved when assessed histologically. Sloughed squamous cells 
were evident on the explants and accumulated in the bottom of the culture dish. To determine if this accumulation 
Figure 3. Stiffness and induced tension in ex vivo esophagus tissues. (a) Stiffness exponent k for strain cycle 
curves fit by tension = A(L/L0)k for basal (cycle 1), extracellular matrix (cycle 2), and carbachol induced (cycle 
3) tissue stiffness (*p < 0.05 vs Cycle 1, +p < 0.05 vs. Cycle 2.) and (b) the corresponding 1 μM carbachol-
induced tension response (*p < 0.05 vs mucosa and lsmb). The data are pooled from samples cultured for 1–14 
days (mean 5.3 days for mucosa, 5.2 days for LSM and 4.6 days for CSM) before measuring stiffness. where n 
represents the number of donors used for each tissue. *p < 0.05 vs Cycle 1, +p < 0.05 vs. Cycle 2.
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represented ongoing squamous differentiation, we gently scraped the surface on an explant to remove the superfi-
cial squamous epithelial cells on day 0 and found that they reaccumulated over 7 days in culture (Fig. 4a).
To validate the potential disease relevance of the ex vivo esophageal platform, we utilized a Th2 cytokine 
cocktail that closely mimics an EoE-like inflammatory milieu to treat mucosal explants. Immunofluorescence 
staining for E-cadherin (Fig. 4b) further confirmed sustained squamous differentiation after 14 days with junc-
tional protein reorganization induced by the cytokine cocktail28. TGFβ1 treatment of LSM bundles also signif-
icantly induced fibronectin and phospholamban expression from 1 to 3 weeks in culture (p < 0.001) (Fig. 4c).
Histologically, collagen I was induced in full thickness ex vivo mucosa after 14 days of treatment with the EoE-like 
cytokine cocktail as compared with vehicle (Fig. 4d).
To demonstrate that the cytokine cocktail induced a molecular EoE-like disease state ex vivo, we utilized the 
Eosinophilic Esophagitis Diagnostic Panel (EDP), a validated transcriptional profile of 96 genes that are dysregulated 
in EoE. Due to the archiving time for some samples, a 50% call rate filter was applied to the 96 genes to focus on the 
informative genes, resulting in a cluster of 60 genes. These data demonstrated that the vehicle treated mucosa retained 
transcription of esophageal genes while the Th2 cytokine cocktail treated mucosa induced a pattern of gene expres-
sion that aligned with the in vivo EoE state (Fig. 5a)29. Principal component analysis demonstrated separation of gene 
expression between the vehicle and cocktail treated mucosa and significant dysregulation of a number of EoE-specific 
genes (Fig. 5b,c). Using a donor whose esophagus met histologic criteria for EoE (epithelial eosinophils of 45 per high 
power field, positive basal zone hyperplasia, 23 eosinophils per high power field in the lamina propria, fibrosis score of 
2), we compared the genes expressed in this donor with the 10 paired vehicle and cytokine-treated mucosa. This anal-
ysis of genes induced >5-fold demonstrated that the inherent esophageal eosinophilic state (red) closely aligned with 
the EoE stated induced ex vivo (blue) by the EoE-cocktail (Fig. 5d).
To better replicate an EoE-like tissue microenvironment, we modelled adoptive transfer techniques used in 
mice30,31 by injecting isolated human peripheral blood eosinophils into the bottom surface of mucosal explants. 
After injection, an eotaxin-1 soaked sponge was laid on the epithelial surface to promote chemotaxis of the 
injected eosinophils. Following 24–72 hours of incubation, eosinophil infiltration, as verified using an eosinophil 
peroxidase (EPX) stain, was present in the lamina propria and epithelium (Supplemental Fig. 1). While we have 
not evaluated secretory properties of the infiltrating eosinophils, these data demonstrate the feasibility of creating 
structural cell dysregulation and an inflammatory environment ex vivo that is similar to EoE.
Functionally, culture of mucosal strips with the Th2 cytokine cocktail induced a significant leftward shift in the 
basal tension versus strain curve after 12–15 days (Fig. 6a). Cocktail-treated as compared to vehicle treated strips 
had a significant increase in tissue stiffness at L = 1.25 L0 as deduced from the value for k (p < 0.001) (Fig. 6b). 
If the averaged stiffness plot is inverted to convey the compliance of the tissue studies (Fig. 6c), the data resem-
bles the compliance curves derived from in vivo EoE endoscopic functional lumen imaging probe (endoFLIP)32. 
Taken together, these data show that treatment of LSM bundles and full thickness esophageal mucosal strips ex 
Figure 4. Properties of esophagus ex vivo. (a) Regeneration of superficial squamous cells of the stratum 
spinosum on day 7 after gentle scraping on day 0 (both untreated). (b) E-cadherin staining demonstrates 
squamous epithelial differentiation in full thickness esophageal mucosal explants cultured ex vivo for 14 days 
in vehicle or Th2 cytokine cocktail. 14 days of Th2 cytokine cocktail causes disruption of the epithelial barrier 
as occurs in the in vivo EoE active disease state. (c) Gene expression of phospholamban (PLN) and fibronectin 
(FBN) in LSM over 4 weeks of TGFβ1 treatment (***p < 0.0001). (d) Collagen1 staining in human esophageal 
mucosa following 14 days of vehicle or Th2 cocktail treatment (black line: epithelium, blue line lamina propia). 
Scale bars represent 50 (a) and 100 (d) microns if not otherwise labeled.
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vivo with a cytokine cocktail similar to the inflammatory cascade seen in EoE can induce alterations in structural 
cell gene transcription and function that aligns with the disease state.
Discussion
In this manuscript, we describe a novel experimental platform to study both baseline and cytokine-modified 
function of human esophageal mucosa and smooth muscle and apply it to recapitulate an EoE-like disease state. 
We reasoned that the mucosa was the most relevant tissue for modelling aspects of EoE as it is the tissue studied 
in patient biopsies. Unlike cell culture or organoid culture, the use of intact mucosal tissue obviates the need 
for cellular disruption and is more likely to accurately translate to the in vivo cell-cell interaction state. We also 
Figure 5. Comparison of the esophageal transcriptome in vehicle treated (blue) and Th2 cytokine cocktail 
(red). Color range is based on log2 normalized intensity (a). Three-dimensional plot containing five paired 
samples (red = cocktail, blue = vehicle) derived from principal component analysis of the genes shown in the 
heat map in order assess the geometric distance between the samples (b). Volcano plot of genes in the EDP with 
FDR p < 0.05, fold change >2 (red, left panel) following treatment with Th2 cytokine cocktail (c). Venn diagram 
comparing the number of genes identified as dysregulated (>5 fold change) in both an organ donor esophagus 
with eosinophilia and samples treated with the cytokine cocktail. Unique and overlapping genes are listed in the 
right panel (d). Mucosa was treated for 72 hours (one paired sample) to 7 days (4 paired samples).
Figure 6. Stiffening esophageal mucosa ex vivo with the Th2 cocktail. (a) Th2 cytokine cocktail shifts the 
tension versus strain to the left indicating shortening and mucosal stiffness. (b) Basal stiffness exponent 
k is significantly increased in mucosal strips treated with Th2 cytokine cocktail. (c) Treatment with Th2 
cytokine cocktail reduces mucosal compliance.
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investigated the mechanical properties of the human esophageal mucosa and muscularis mucosa which have not 
been previously measured ex vivo. Many studies have focused on lower esophageal sphincter function33,34, and 
a single study reports that human esophageal CSM and LSM are remarkably compliant with maximal tension 
development at twice the resting length35. We confirmed these findings and further demonstrated that the esoph-
ageal mucosa was highly compliant at baseline and that both isolated smooth muscle bundles and intact mucosa 
responded functionally to the acetylcholine analogue carbachol even after culture for many days.
The value of this approach is supported by the ability of our esophageal mucosa platform to mimic EoE at the 
levels of global transcriptional induction as assessed by the EDP transcription profile and alterations in esoph-
ageal stiffness. Treatment with an EoE-like Th2 cytokine cocktail induced disease-relevant gene transcription, 
alterations in E-cadherin organization of the epithelial barrier as occurs in vivo in the active EoE disease state28, 
and also increased mucosal stiffness leading to compliance properties similar to those obtained from EoE patients 
during endoFLIP36. Given this applicability of the platform to one esophageal disease, we suggest that our studies 
could help investigators to elucidate esophageal function in response to various stimuli including cytokines, acid, 
carcinogens, and therapeutic drugs. Since the mucosa and muscle bundles are in an intact tissue, cell-cell and 
cell-matrix communication is not breached which may lend a deeper understanding of tissue responses. Indeed, 
our studies indicate that changes in mucosal stiffness can be mediated, at least in part, by alterations in smooth 
muscle contraction. Although a simplification of the underlying processes, our results point to 2 distinct addi-
tive mechanisms with the potential to account for increased stiffness in the EoE esophagus – (1) altered smooth 
muscle stiffness due to altered actin-myosin (revealed by responses to carbachol and histamine) and (2) altered 
extracellular matrix stiffness (revealed by loss of smooth muscle-mediated elastic recoil with strain).
By using exogenous recombinant Th2 and fibrotic cytokines, we have tried to closely recapitulate the cytokine 
milieu of EoE as proof of principle that the ex vivo human mucosa could be used to study disease specific path-
ways. However, we acknowledge the weaknesses in our current system including the lack of infiltrating inflam-
matory cells, a failure to maintain/reconstitute a thick squamous layer, and the lack of altered extracellular matrix 
thickness visible on hematoxylin and eosin staining. These issues could be addressed in the future by using longer 
term culture, by injecting and promoting transmigration of inflammatory cells into the tissue (which we have 
shown herein is feasible for eosinophils), and by the activation of mast cells in situ using anti-IgE antibodies.
Our ex vivo culture approach is also limited to the analysis of individual tissue layers (mucosa, CSM, LSM) to 
permit adequate gas, nutrient and metabolite exchange between the tissue and medium. An implicit assumption 
in our approach is that studies using human tissue will yield results more translatable to human disease than stud-
ies in non-human model organisms like the mouse. While demonstration of this being the case or not is beyond 
the scope of this manuscript, we can say that a human EDP is not directly applicable to mice. Conversely, targeted 
gene disruption in human tissue explants is not efficient. Thus, the strongest experimental approaches will likely 
couple studies in mice and humans.
Our experiments demonstrate the feasibility of the human tissue approach for EoE. Although human tissue 
acquisition is unpredictable, the ability to maintain functional responses to carbachol and histamine over days 
to weeks allow experimental flexibility in timing. In addition, tissues remained functional despite transport from 
Arkansas to San Diego, allowing collaboration between labs at large distances. Future experiments to further val-
idate the platform are warranted. We think our ability to experimentally model an EoE-like disease state ex vivo, 
using shared tissue should promote further collaborative efforts between esophageal disease investigators.
Methods
Human esophagus acquisition. Viable human esophagi were procured by the National Disease Research 
Interchange or the Arkansas Regional Organ Recovery Agency from deceased organ transplant donors. Criteria 
for organ selection included <10 pack year history of smoking, no cancer, no infection and no more than 2 
chronic diseases reported. Esophagi were packaged and transported under transplant conditions to the Kurten 
laboratory within 24 hours. The acquisition and use of tissue from cadaveric donors was not found to constitute 
human subjects research (University of Arkansas for Medical Sciences IRB) and was IRB exempt (University of 
California, San Diego). The donor demographics are summarized in Supplemental Table 1. Individual donor 
characteristics and their use in experiments is detailed in supplemental Table 2.
Human esophageal tissue preparations. The distal two-thirds of the human esophagus were excised in the Kurten 
laboratory. The esophagus initially was cut into 5 cm thick rings. These rings were used intact or separated into 
longitudinal (LSM) and circular smooth muscle (CSM) rings for isometric tension measurements.
Mucosal Strip and Muscle Bundle Preparations. The distal 6–9 cm of the esophageal body 1 cm above the gas-
troesophageal junction and below the skeletal muscle (recognizable as red longitudinal bundles) was excised, 
cut longitudinally, placed mucosal side up, washed extensively, and cut laterally into ~15 mm wide large strips of 
mucosa with associated muscularis propria (Fig. S2). The intact mucosal layer (epithelium, subepithelial lamina 
propria, and muscularis mucosa [MM]) was separated from the muscularis propria by sharp dissection through 
the Meissner’s plexus. These mucosal strips (15 × 60 × 4 mm) were cut into smaller strips (1–2 mm wide) along 
the longitudinal axis of the esophagus after removing residual Meissner’s plexus.
Adventitia was dissected away from the muscularis propria under a dissecting microscope to reveal the under-
lying LSM bundles which were separated from the CSM via dissection through the myenteric (Auerbach’s) plexus. 
Dissected tissues were either cultured immediately or stored for 1–4 days at 7 °C in an organ preservation solution 
(SPS-1, Organ Recovery Systems, Chicago, Il)37.
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Ex vivo culture. Full thickness mucosa, isolated MM, LSM, and CSM were cultured in 24-well plates in 
300  μL/well DMEM:F12 changed every 2–3 days and supplemented with penicillin (100 units/ml), streptomycin 
(100 µg/ml), Amphotericin B (0.25 µg/ml), and 0.5% Primocin (InvivoGen, San Diego, CA) at 37 °C, 5% CO2 in 
a humidified incubator with continuous agitation. The Th2-fibrosis cocktail contained: TGFβ1 (1 ng/ml), IL-13 
(5 ng/ml), IL-4 (1 ng/ml), IL-2 (10 ng/ml), IL-9 (10 ng/ml), LIGHT/TNSF14 (10 ng/ml), histamine (1 μM) in 
DMEM:F12 supplemented with bovine serum albumin (1 mg/ml), which also served as the vehicle control.
Measurements of tension and tissue stiffness. Tension measurements. Muscle bundles or mucosal 
strips were hung vertically from Radnoti (Monrovia, CA) force transducers (range 0–20 g) with a stiff wire in 
35 ml tissue baths (Krebs Henseleit buffer, Sigma Chemical Company, St Louis, Mo, aerated at 37 °C) for isomet-
ric force measurements along the long axis of the tissue. The force transducer output was zeroed and samples 
were stretched until an initial stable force could be measured (~1mN, with a full-scale deflection of 196 mN). 
Average tension (=force/mass/length; mN/mm2) was calculated and plotted as a function of strain (L/Lo, where 
L = the measured length; L0 = reference length measured at tissue preparation before tying suture loops at each 
end). Tissue length (corrected for shortening in culture and for L0) was measured at the beginning and end of the 
experiment and wet tissue mass was measured at the end of the run.
Stiffness measurements. Tissue was lengthened stepwise in 0.8 mm increments at 2 minute intervals using 
an automated micrometer screw driven linear translation stage to which the force transducers were attached. 
Force transducer output was logged at 5 second intervals. At each step, an initial instantaneous increase in force 
occurred that then stabilized at a lower level within 2 minutes. Lengthening was reversed when the average force 
reading exceeded 40 mN (corresponding to ~30mN/mm2 tension). At each shortening step, an initial decrease 
in force occurred that subsequently stabilized. Given these kinetics, tension responses were averaged over the 
2 minute lengthening or shortening interval.
Tissue stiffness (mN/mm2/mm displacement) was calculated for each bundle from the derivative of the power 
function tension = A (L/L0)k, where the scaling factor A is eb with b and k determined by least squares linear 
regression of double natural log transformed data (r2 typically exceeded 0.9 with >5 data pairs). For L/Lo = 1, A 
is the tissue tension (or stress) and Ak is stiffness. In most experiments, tissue was shortened stepwise to baseline, 
and, after allowing at least 4 minutes for the force output to stabilize, challenged with 1 μM carbachol.
RNA analysis and immunostaining. RNA was extracted from full thickness mucosa or LSM as previ-
ously described13. Paraffin embedded full thickness mucosa was used in immunohistochemistry as previously 
described13. Infiltrating intact eosinophils and eosinophil degranulation (i.e., the presence of free cytoplasmic 
granules and/or tissue deposition of eosinophil granule proteins) were assessed by immunohistochemistry using 
a mouse monoclonal anti-eosinophil peroxidase antibody (EPX-mAb) as previously described38,39. Tissue sec-
tions were digitized (Aperio AT Turbo, Leica Biosystems, Buffalo Grove, IL) and images were generated using 
Aperio ImageScope software (version 11.2.0.780, Aperio Technologies, Vista, CA).
eosinophil isolation. Human eosinophils were isolated from peripheral blood by negative selection40. 
Sodium citrate was used as an anticoagulant and hetastarch (6%, StemCell Technologies) was then added to 
the syringes and red blood cells are allowed to sediment by gravity. The red blood cell depleted layer was then 
collected and layered over Ficoll-Paque Premium (GE Healthcare), followed by centrifugation. At the end of cen-
trifugation, a granulocyte-enriched population, consisting mainly of neutrophils and eosinophils, was present in 
a pellet at the bottom of the tube and collected. The collected granulocytes are then washed and incubated with 
an antibody cocktail with antibodies against CD2, CD14, CD16, CD19, CD56, and glycophorin A (StemCell 
Technologies). A colloid suspension consisting of magnetic beads that bind to these negative selection antibodies 
was added, followed by passage over a magnetized column. The effluent contained the purified eosinophil popu-
lation. Eosinophil purity, assessed by Hema-3 staining (Fisher Scientific) of a cytocentrifuge smear, was routinely 
greater than 97–99%.
Mucosal injection of eosinophils. Isolated human eosinophils were kept in IL-5 until use to ensure lon-
gevity and injected (80,000 eosinophils per mucosal explant on a transwell chamber) at the serosal surface of 
mucosa. IL-13 (10 ng/ml) was added to the basal medium and an eotaxin-1 soaked sponge was placed on the 
epithelium. Mucosal explants were cultured in DMEM:F12 for 24–72 hours, collected, paraffin embedded and 
stained with hematoxylin and eosin or EPX and analyzed for the location of eosinophils in the mucosa. Sham 
injection was utilized to assess tissue damage and a time 0 mucosa was collected to assess the starting location of 
the eosinophils in the tissue.
Transcription array analysis. The molecular signature was acquired by EoE diagnostic panel (EDP) quan-
tified by a 96 gene RNA expression signature array at Cincinnati Children’s Hospital Medical Center, as reported 
previously29. Briefly, 500 ng of RNA from tissue sample was reverse transcribed to cDNA and subjected to EDP 
amplification by using the ABI 7900HT qPCR system (Applied Biosystems, Foster City, Calif). To compensate 
for the long archiving time for some of the samples, a 50% call rate filter was applied to the 96 esophageal genes to 
focus on informative genes, resulting in a cluster of 60 genes. The data were then imported into GeneSpring (GX 
12.6) software for implementation of the analyses.
The transcriptomes of the 10 paired samples from 5 independent donors were compared by using the 
unsupervised clustering analysis, principal component analysis (PCA), and the paired t test adjusted with the 
Benjamini-Hochberg method. Clustering was performed by hierarchical clustering design, with the Euclidean 
distance metric and the Wald’s linkage rules. Condition and gene entity are 2-D clustered in conjunction with 
expression heat map with red being up-regulation and blue being down-regulation. PCA was used to generate a 
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3-dimensional plot of the top 3 variance contributors between vehicle and post treatment by fibrotic cocktail. The 
paired t test adjusted with the Benjamini-Hochberg method was used to compare the treatment effect of paired 
samples before and after fibrotic cocktail, visualizing by a volcano plot (log2 fold change as x-axis and −log10 
adjusted P value as y-axis). A 2-tailed adjusted P-value of less than 0.05 was deemed statistically significant.
statistics. GraphPad Prism was used for graphing statistics (unpaired, 2-tailed t-test or Spearman’s corre-
lation coefficient <0.05 was considered significant). Experiments were repeated using >2 donors in triplicates.
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